Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 2/20 | 0.38 |
| ▸ | ARG2 | P78540 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099388 | 0.86 | KCNA3 (0.42) | KCNA3SPHK1ARG1ARG2TERT | |
| SCHEMBL1361941 | 0.86 | — | — | |
| SCHEMBL4022189 | 0.84 | KCNA3 (0.41) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL8015295 | 0.82 | SPHK1 (0.42) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL8022491 | 0.82 | SPHK1 (0.42) | KCNA3SPHK1ARG1ARG2HRH3 | |
| SCHEMBL21386103 | 0.80 | KCNA3 (0.44) | KCNA3SPHK1ARG1ARG2TERT | |
| SCHEMBL1259722 | 0.79 | — | — | |
| SCHEMBL916463 | 0.77 | SLC18A3 (0.48) | KCNA3SPHK1ARG1ARG2GPR119 | |
| SCHEMBL5069750 | 0.77 | HRH3 (0.34) | HRH3 | |
| SCHEMBL1316224 | 0.76 | LTA4H (0.40) | ARG1ARG2HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| EP-1780197-B9 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-04-06 | — | — | EP | claimed |
| EP-1780197-B1 | 5-SUBSTITUTED-2-PHENYLAMINO BENZAMIDES AS MEK INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-10-20 | — | — | EP | claimed |
| US-7745663-B2 | 5-Substituted-2-phenylamino benzamides as MEK inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-06-29 | — | — | US | claimed |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-09-17 | — | — | US | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | claimed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004108711-A1 | PYRAZINIL QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004108704-A1 | PYRIMIDIN-4-YL 3-CYANOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | claimed |
| WO-2004069827-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004069250-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| WO-2003048159-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | KCNA3 832/4885SPHK1 1938/4885ARG1 28/4885 |
| US-20090233915-A1 | 5-Substituted-2-Phenylamino Benzamides as MEK Inhibitors | BRAF, RAF1, NRAS | KCNA3 1972/4885SPHK1 954/4885ARG1 670/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | KCNA3 1902/4885SPHK1 4306/4885ARG1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.